Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Jennifer L, Willcox"'
Autor:
Christian M. Leutenegger, Michelle D. Evason, Jennifer L. Willcox, Haresh Rochani, Holly L. Richmond, Cathy Meeks, Cecilia E. Lozoya, Jeffrey Tereski, Samantha Loo, Kelly Mitchell, Jan Andrews, Christian Savard
Publikováno v:
International Journal for Parasitology: Drugs and Drug Resistance, Vol 24, Iss , Pp 100520- (2024)
Surveillance data for Ancylostoma spp. and the A. caninum benzimidazole treatment resistance associated F167Y polymorphism using molecular diagnostics was obtained in a large population of dogs from the United States and Canada. Real-time PCR (qPCR)
Externí odkaz:
https://doaj.org/article/38d6b6fed1bb4e4fa7ca1202b7594cd0
Autor:
Christian M. Leutenegger, Cecilia E. Lozoya, Jeffrey Tereski, Jan Andrews, Kelly D. Mitchell, Cathy Meeks, Jennifer L. Willcox, Gregory Freeman, Holly L. Richmond, Christian Savard, Michelle D. Evason
Publikováno v:
Parasites & Vectors, Vol 16, Iss 1, Pp 1-10 (2023)
Abstract Background For decades, zinc sulfate centrifugal fecal flotation microscopy (ZCF) has been the mainstay technique for gastrointestinal (GI) parasite screening at veterinary clinics and laboratories. Elsewhere, PCR has replaced microscopy bec
Externí odkaz:
https://doaj.org/article/f7d7e13868d949069400823ac310d6a3
Publikováno v:
Frontiers in Veterinary Science, Vol 8 (2021)
Zoledronic acid (ZOL) is an intravenous bisphosphonate indicated for the use of hypercalcemia of malignancy and management of bony metastases. Its therapeutic effect lies in the targeting of malignant osteoclasts; however, administration can be assoc
Externí odkaz:
https://doaj.org/article/fd04cdd6441d42f78f9db4fc82e9d3b0
Autor:
Sami Al-Nadaf, Robert B. Rebhun, Kaitlin M. Curran, Rachel O. Venable, Katherine A. Skorupski, Jennifer L. Willcox, Jenna H. Burton
Publikováno v:
BMC Veterinary Research, Vol 14, Iss 1, Pp 1-8 (2018)
Abstract Background A doxorubicin (DOX)-based chemotherapy protocol, CHOP, is the most effective treatment for canine high-grade B-cell lymphoma; however, the cost and time requirements associated with this protocol are not feasible for many pet owne
Externí odkaz:
https://doaj.org/article/40e72e53425e447e93c72d615b5c02a3
Autor:
Sridhar Veluvolu, Jennifer L. Willcox, Katherine A. Skorupski, Sami Al‐Nadaf, Robert Rebhun, Luke Wittenburg
Publikováno v:
Veterinary and comparative oncology, vol 21, iss 1
Vet Comp Oncol
Vet Comp Oncol
Cyclophosphamide (CP) is an alkylating agent commonly included in multi-drug treatment protocols for canine cancer. As a prodrug, CP requires hepatic metabolism for activation to the intermediate compound 4-hydroxycyclophosphamide (4-OHCP) which then
Publikováno v:
Frontiers in Veterinary Science, Vol 6 (2019)
Positron Emission Tomography (PET) is an imaging technique that provides functional information, in addition to structural information obtained with computed tomography (CT). The most common application is cancer staging, using 18F-Fluorodeoxyglucose
Externí odkaz:
https://doaj.org/article/1ef5a8b6776c49f4a3749ec1af6f3029
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Table 3 contains a summary of the outcomes, with statistical comparisons, of the dogs enrolled in the SOC clinical trial arm. This includes the DFI and outcomes of the groups of dogs stratified by tumor location and ALP status.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cf79f886bb73370f4df3bf2b203861b
https://doi.org/10.1158/1078-0432.22478240
https://doi.org/10.1158/1078-0432.22478240
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Fig. 1 depicts the chronology of clinical trial visits and associated procedures for dogs enrolled in this clinical trial.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e206106b269e032e0544bf85a04ba6
https://doi.org/10.1158/1078-0432.22478255
https://doi.org/10.1158/1078-0432.22478255
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Table 2 contains the summary comparison of both the Intent-to-treat and Per-protocol analyses of clinical outcomes for dogs enrolled in Standard of Care (SOC) and Standard of Care + sirolimus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22720df435a1efb42466d847b634528d
https://doi.org/10.1158/1078-0432.22478243.v1
https://doi.org/10.1158/1078-0432.22478243.v1
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Purpose:The mTOR pathway has been identified as a key nutrient signaling hub that participates in metastatic progression of high-grade osteosarcoma. Inhibition of mTOR signaling is biologically achievable with sirolimus, and might slow the outgrowth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84d6627db92e6f7818bf68c257932e98
https://doi.org/10.1158/1078-0432.c.6529898
https://doi.org/10.1158/1078-0432.c.6529898